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Severe dengue virus infection can occur in
humans with pre-existing antibodies against
the virus. This observation led to the hypothesis
that a subneutralizing antibody level in vivo can
increase viral burden and cause more severe
disease. Indeed, antibody-dependent enhance-
ment of infection (ADE) in vitro has been
described for multiple viruses, including the
flaviviruses dengue virus and West Nile virus.
Here, we demonstrate that the complement
component C1q restricts ADE by anti-flavivirus
IgG antibodies in an IgG subclass-specific
manner in cell culture and in mice. IgG sub-
classes that avidly bind C1q induced minimal
ADE in the presence of C1q. These findings
add a layer of complexity for the analysis of
humoral immunity and flavivirus infection.
INTRODUCTION
The genus Flavivirus is composed of 73 viruses, 40 of
which are associated with severe human diseases includ-
ing West Nile (WNV), yellow fever (YFV), Japanese en-
cephalitis (JEV), and dengue (DENV) viruses (Burke and
Monath, 2001). This clinically important group of arthro-
pod-borne viruses shares a common nucleic acid genome
structure (positive-polarity, 11 kilobase single-stranded
RNA), organization (three structural and seven nonstruc-
tural proteins), particle size (500 A˚), and cellular life
cycle. Studies by several groups have established that hu-
moral immunity to flavivirus infection is necessary and suf-
ficient for host protection from disease (Ben-Nathan et al.,
2003; Diamond et al., 2003a, 2003b; Oliphant et al., 2005,
2006; Roehrig et al., 2001; Schlesinger et al., 1985; Tesh
et al., 2002). Following infection, the majority of neutraliz-
ing antibodies are directed against the flavivirus envelopeCell Host &(E) protein, although some likely recognize the premem-
brane/membrane (prM/M) protein (Colombage et al.,
1998; Falconar, 1999; Pincus et al., 1992; Vazquez et al.,
2002). Antibody protection in vivo generally correlates
with neutralizing activity in vitro (Kaufman et al., 1987;
Phillpotts et al., 1987; Roehrig et al., 2001). However,
Fc-dependent effector functions also contribute to the
protective activity of at least some anti-flavivirus anti-
bodies in vivo (Oliphant et al., 2005).
Paradoxically, Fc-g receptor (Fc-gR) engagement by
antibodies in vitro also has been observed to enhance rep-
lication of flaviviruses (Gollins and Porterfield, 1984, 1985;
Halstead and O’Rourke, 1977; Kliks, 1990; Kliks et al.,
1989; Peiris et al., 1981; Peiris and Porterfield, 1979). At
concentrations that do not reach the stoichiometric
threshold necessary for neutralization, anti-flavivirus anti-
bodies enhance infection in cells expressing activating
Fc-gR (Pierson et al., 2007). This phenomenon, also
known as antibody-dependent enhancement of infection
(ADE) is hypothesized to contribute to the pathogenesis
of secondary DENV infection (Halstead, 2003), and possi-
bly, the adverse effects following challenge of individuals
immunized with some formalin-inactivated viral vaccines
(Iankov et al., 2006; Ponnuraj et al., 2003; Porter et al.,
1972; Prabhakar and Nathanson, 1981). Despite its exten-
sive characterization in vitro, and its possible epidemio-
logical link to the pathogenesis of dengue hemorrhagic
fever (DHF), the significance of ADE for DENV and other
flaviviruses in vivo remains controversial (Barrett and
Gould, 1986; Goncalvez et al., 2007; Gould and Buckley,
1989; Gould et al., 1987; Halstead, 1979; Rosen, 1989;
Wallace et al., 2003). Part of this controversy stems from
an inability to establish reproducible models of ADE in
small animal models.
The Fc region of IgG also activates the complement sys-
tem through the classical pathway (Volanakis, 2002).
Complement is a family of serum proteins that interact in
a serine protease catalytic cascade leading to the release
of proinflammatory peptides, attachment of opsonins, and
formation of the membrane attack complex (MAC). TheMicrobe 2, 417–426, December 2007 ª2007 Elsevier Inc. 417
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C1q Inhibits ADE of Flavivirusescomplement opsonin C1q binds to the heavy chain CH2
constant region of IgG (Duncan and Winter, 1988; Iduso-
gie et al., 2000) and activates the classical pathway C3
convertase, which promotes C3b opsonization and for-
mation of the C5-C9 MAC (Volanakis, 2002). Complement
activation augments the neutralizing activity of antiviral
antibodies against measles (Iankov et al., 2006), influenza
(Feng et al., 2002; Mozdzanowska et al., 2006), vesicular
stomatitis (Beebe and Cooper, 1981), hepatitis C (Meyer
et al., 2002), and human immunodeficiency (Aasa-Chap-
man et al., 2005; Spruth et al., 1999) viruses. In contrast,
the addition of serum complement to anti-WNV IgM en-
hanced infection in macrophages (Cardosa et al., 1983,
1986).
Herein, we investigate the role of complement in modu-
lating ADE of anti-flavivirus IgG. We identify C1q as the
serum component necessary and sufficient to restrict
ADE in vitro in an IgG subclass specific manner. Based
on these findings, we used C1q/ mice to demonstrate
in vivo the IgG subclass-specific requirements for the
development of ADE.
RESULTS
At subneutralizing concentrations, antibody can enhance
infection of flaviviruses in Fc-gR-expressing cells (Hal-
stead, 2003; Pierson et al., 2007). To test for the effect
of C1q or any specific complement component on ADE,
we used a highly quantitative, flow cytometric-based
functional assay with WNV reporter virus particles (RVP)
(Pierson et al., 2006, 2007). RVP are virus-like particles
composed of the structural proteins of WNV and a subge-
nomic replicon encoding a reporter gene. RVP are capa-
ble of only a single round of infection and allow virus entry
to be measured as a function of reporter gene activity.
WNV RVP were incubated with purified mouse mAbs in
the presence of fresh mouse serum prior to infection of
K562 cells, a human erythroleukemia cell line that ex-
presses high levels of the activating Fc-g receptor IIa
(FcgRIIa) and has been used to study ADE of flaviviruses
in vitro (Littaua et al., 1990; Pierson et al., 2007). In the ab-
sence of serum, RVP mixed with serial dilutions of
a strongly neutralizing IgG2b mAb (E16) that binds domain
III (DIII) of WNV E protein (Oliphant et al., 2005) promoted
a biphasic infection pattern characteristic of ADE (Morens
et al., 1987; Pierson et al., 2006, 2007). Strikingly, the ad-
dition of 5% fresh mouse serum almost completely abol-
ished E16-mediated enhancement, reducing the peak
WNV infection by 37-fold (Figure 1A, p = 0.002, n = 9).
The serum-dependent inhibition of ADE was inactivated
by heat and required C1q but not C3, mannose-binding
lectins (MBL), factor B (fB), or C5 as determined by ex-
periments with C1q/, C3/, MBL/, fB/, or C5/
serum (Figure 1B and data not shown). Purified C1q eli-
cited the same effect as wild-type mouse serum, reducing
peak E16-enhancement 60-fold (p = 0.02, n = 4). Similar
results were observed with E24, an epitope-matched
IgG2a (Figures 1C and 1D). However, neither serum nor
purified C1q inhibited ADE induced by the epitope-418 Cell Host & Microbe 2, 417–426, December 2007 ª2007 Ematched IgG1 mAb, E34 (Figure 1E, p > 0.8, n = 3, and
data not shown). Studies were repeated with three, more
weakly neutralizing DII fusion-loop-specific anti-E anti-
bodies, E18, E28, and E60, which enhance WNV infection
in cells expressing Fc-gR (Oliphant et al., 2006). Analo-
gously, purified C1q inhibited ADE induced by the IgG2a
mAbs E18 and E60 (43- to 136-fold, Figures 1F and 1G,
p % 0.04, n > 3), but not that induced by the epitope-
matched IgG1 mAb E28 (Figure 1H).
Mouse macrophages express multiple activating Fc-gR
(I, III, and IV) and are permissive for WNV in vivo (Samuel
and Diamond, 2005). To determine the effect of C1q in
a more relevant in vitro infection model, primary mouse
macrophages were exposed to infectious WNV (New
York 2000 strain) that was preincubated with antibody in
the presence of mouse serum or purified C1q. Analogous
to the RVP assays, we observed a 35-fold enhancement of
infection in the presence of E16 (Figure 1K), and peak ADE
was inhibited18-fold by the addition of either mouse se-
rum or purified C1q (p% 0.001, n = 6). Correspondingly,
no difference in enhancementwas observed using the epi-
tope-matched IgG1mAb, E34 (Figure 1L). These data con-
firm that C1q reduces ADE of live WNV infection in cell
types that express multiple Fc-gR and are relevant in vivo.
To verify that this phenotype was not specific to mouse
mAbs, we engineered human IgG subclass switch variants
of E16 and tested for ADE in cells expressing human
Fc-gRIIa. As expected, ADE by the four human IgG sub-
classes of E16 was observed (Figure 2). However, there
was an 50-fold difference in the peak ADE induced by
the different switch variants, corresponding to the relative
affinity of the IgG subclasses for Fc-gRIIa (Hulett and
Hogarth, 1994; Ravetch and Kinet, 1991). When C1q
was added, peak ADE by E16 hu-IgG3 was markedly di-
minished (9-fold, p < 0.0001, n = 8, Figure 2C). In contrast,
C1q had no effect on ADE by E16 hu-IgG2 (Figure 2B) or
hu-IgG4 (Figure 2D) and a lesser inhibitory effect on E16
hu-IgG1 (3-fold, p = 0.03, n = 5, Figure 2A). The effect
on E16 hu-IgG1-mediated ADE by C1q was not dose-
dependent, as similar fold reductions were observed
when C1q concentrations were varied in the physiologic
range between 50 and 200 mg/ml (Figure S1A in the Sup-
plemental Data available with this article online). These
data establish that C1q inhibits ADE of human anti-flavivi-
rus IgG in a subclass-dependent manner.
As only a small subset of individuals with pre-existing
anti-DENV antibodies develop DHF on secondary chal-
lenge with a heterologous serotype (Halstead, 1989), we
hypothesized that C1q binding to antibody-opsonized
DENV could restrict ADE and possibly disease. To begin
to address this, DENV type 1 (DENV-1) RVP were incu-
bated with increasing concentrations of two flavivirus
crossreactive, DII-specific, epitope-matched mAbs E18
(IgG2a) and E28 (IgG1) in the presence of purified C1q prior
to infection. In the absence of C1q, incubation with E18 or
of E28 resulted in an average peak of 25- and 108-fold
enhancement of infection, respectively (Figures 1I and
1J). Purified C1q inhibited E18-dependent ADE 43-fold
(p = 0.04, n = 4), but not that induced by E28 (p > 0.6,lsevier Inc.
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C1q Inhibits ADE of FlavivirusesFigure 1. Mouse Serum or C1q Modu-
lates mAb Enhancement of WNV and
DENV Infection
(A) Serial dilutions of E16 (mouse IgG2b) were
mixed with media and 5% fresh or heat-inacti-
vatedmouse serum, incubated withWNV RVP,
and added to FcgRIIa+ K562 cells. Forty-eight
hours later, cells were analyzed by flow cytom-
etry for GFP expression. The data are ex-
pressed as the fold enhancement of infection
compared to no antibody, and one representa-
tive experiment of five is shown.
(B) Experiments were performed as in (A) ex-
cept that fresh C1q/ or C3/ serum or puri-
fied C1q (50 mg/ml) was mixed with the mouse
E16 mAb.
(C–E) Experiments were performed as in (A)
and (B) except that the epitope matched DIII-
specific E24 (mouse IgG2a) (C and D) or E34
(mouse IgG1) (E) mAbs were used.
(F and G) Experiments were performed as
above except that the flavivirus crossreactive
DII-specific IgG2a mAbs E18 (F) or E60 (G)
were used.
(H) Experiments were performed as above ex-
cept the flavivirus crossreactive DII-specific
IgG1 mAb E28 was used.
(I and J) Serial dilutions of the flavivirus cross-
reactive E18 (IgG2a) (I) or E28 (IgG1) (J) were
mixed with DENV1 RVP in the presence or ab-
sence of C1q and added to K562 cells.
(K and L) Serial dilutions of E16 (IgG2b) (K) or
E34 (IgG1) (L) were mixed with infectious
WNV in the presence or absence of C1q and
added to mouse macrophages. One day later
supernatants were harvested and titered by
plaque assay. The data from one representa-
tive experiment of six are shown and ex-
pressed as infectious plaque-forming units
(PFU) per ml. Statistical analysis is described
in the text. Error bars indicate standard devia-
tions.n = 2). Thus, C1q also limits ADE of DENV infection in an
IgG subclass-specific manner.
Polyclonal antibodies against viruses are of mixed IgG
subclass, antigen specificity, and affinity. To determine if
C1q modulates ADE induced by polyclonal antibodies,
we incubated WNV or DENV RVP with C1q and immune
IgG from WNV-challenged mice, heat-inactivated serum
from convalescent WNV patients, or umbilical cord blood
samples from DENV-immune mothers. The latter speci-
men are particularly relevant, as they contain IgG that is
passively transferred to the fetus during gestation; these
antibodies are believed to account for the increased risk
of severe DHF/Dengue shock syndrome (DSS) during
the first 6–9 months of human life (Kliks et al., 1988).
Mouse immune IgG against WNV enhanced infection
350-fold compared to nonimmune murine IgG (Fig-
ure 3A, p = 0.03, n = 3), and purified human C1q reduced
this enhancement 39-fold (p = 0.02, n = 3). Similarly, all
WNV and DENV patient immune sera enhanced WNV
and DENV-1 infection (Figures 3B–3F and Figure S2), re-
spectively. However, marked differences in the ability ofCell Host &C1q to inhibit ADE were observed. For example, in some
patient sera, C1q nearly abolished ADE, reducing en-
hancement25-fold (Figure 3C, p = 0.05, n = 3, Figure S2),
whereas in others the effect was modest, with an 3-
to 4-fold reduction (Figures 3B, 3D, and 3F, Figure S2,
p % 0.02, n = 3). Finally, in other samples (Figure 3E),
C1q had virtually no effect on reducing ADE. Analogous
to experiments with hu-E16 mAbs, higher concentrations
of purified C1q did not further restrict ADE by polyclonal
sera (Figure S1B). Thus, C1q modulates WNV and DENV
ADE induced by polyclonal antibodies, but to different
degrees depending on the individual sample.
Based on our in vitro data, we hypothesized that
C1q could limit ADE in vivo. To test this, wild-type and
C1q/ mice were passively administered DII (E18 and
E28) and DIII-specific (E16, E24, and E34) mouse mAbs
of different IgG subclasses 1 day prior to WNV infection.
Four days later, spleen tissues were titrated for viral bur-
den. The spleen was examined because Fc-gR-express-
ing macrophages are targets for WNV infection in this
tissue (Samuel and Diamond, 2005). Notably, ADE wasMicrobe 2, 417–426, December 2007 ª2007 Elsevier Inc. 419
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C1q Inhibits ADE of Flavivirusesdetected significantly at only onemAb dose (0.1 ng) and at
low levels (1.5- to 2.3-fold, p% 0.05) in wild-type mice re-
ceiving the DII- or DIII-specific mIgG1 mAbs, which bind
C1q poorly (Figures 4A and 4B). As expected, this modest
enhancementwas abrogated in congenicmice that genet-
ically lack activating Fc-gR (Figures 4D and 4E). ADE was
not observed (p > 0.7) at any dose in wild-type mice with
DII-specific E18 (mIgG2a) or DIII-specific E16 (mIgG2b)
mAbs, which are predicted to bind C1q avidly (Figures
4A and 4B). Passive transfer experiments were also per-
formed in wild-type mice with human IgG subclass vari-
ants of E16 that bind C1q poorly (IgG2 and IgG4) or
strongly (IgG3); no significant ADE of WNV infection
in vivowas observedwith any of these E16 human IgG var-
iants (Figure 4C). In contrast, passive transfer of 10 and
100 ng of the DII-specific E18 (mIgG2a) to C1q
/ mice
enhanced WNV infection 4- to 15-fold in the spleen (Fig-
ure 4F, p % 0.05). Transfer of 100 ng of the DII-specific
E28 (mIgG1) also showed modest enhancement in the ab-
sence of C1q. Analogously, passive transfer of several
doses of the DIII-specific E24 (mIgG2a) strongly enhanced
WNV infection (1.5- to 22-fold, p% 0.05) in C1q/ mice,
whereas transfer of the epitope-matched E34 (mIgG1) had
little enhancing effect (Figure 4G). Somewhat unexpect-
edly, E16, the DIII-specific mouse IgG2b, did not promote
significant ADE in the spleen ofC1q/mice, despite test-
ing across a 4-log dose range (Figure 4G). Similar results
were observed with the two human IgG subclass variants
of E16 that most avidly bind C1q; despite robust ADE
Figure 2. C1qModulates ADE by Human IgG Subclass Switch
Variants of E16 in K562 Cells
Serial dilutions of E16 hu-IgG1 (A), hu-IgG2 (B), hu-IgG3 (C), and hu-
IgG4 (D) were mixed with WNV RVP in the presence or absence of
C1q prior to infection of FcgRIIa+ human K562 cells. Cells were har-
vested 48 hr after infection and processed by flow cytometry. The
data are expressed as the fold enhancement of infection compared
to no antibody, and one representative experiment of three is shown.
Statistical analysis is described in the text. Error bars indicate standard
deviations.420 Cell Host & Microbe 2, 417–426, December 2007 ª2007 Ein vitro in humanK562 cells in the absence of C1q (see Fig-
ure 2), little, if any, ADE was observed in C1q/mice with
E16 hu-IgG1 or hu-IgG3 over a wide range of antibody
doses (Figure 4H). Thus, in wild-type mice, ADE of WNV
infection occurs in vivo in a very limited manner, and
only with mAbs (mIgG1) that bind C1q poorly. In C1q
/
mice, ADE occurs more significantly with some mAbs of
the mIgG2a subclass. Although we reproducibly detected
ADE of WNV infection in vivo with specific mAbs, no in-
crease in lethality or change in disease phenotype was ob-
served (data not shown), possibly because of the relatively
flat dose-response curve of WNV disease in C57BL/6
mice (Diamond et al., 2003a).
DISCUSSION
Although ADE is readily observed in vitro with a number of
viruses, it has been difficult to establish consistently in vivo
in animal models.While our data suggest that ADE can oc-
cur in vivo, it does so under a restricted set of conditions
that is modulated in part by C1q binding to individual
IgG subclasses. In wild-type C1q-sufficient mice, ADE
was observed at relatively low levels and only with mAbs
of the mouse IgG1 subclass, which poorly bind C1q. At
present, it remains unclear why DII- or DIII-specific IgG1
mAbs did not enhance infection more strongly. However,
this small enhancement in vivo strictly depended on ex-
pression of activating Fc-gR. In contrast, in C1q/
mice, robust ADE was observed with DII- or DIII-specific
IgG2a mAbs; as these mAbs are predicted to bind C1q av-
idly, their inability to induce significant ADE inC1q+/+wild-
type mice is consistent with their role in C1q-mediated in-
hibition of ADE. Surprisingly, the DIII-specific IgG2b mAb
E16 did not promote significant ADE of WNV in C1q/
mice, possibly due to the affinity of this IgG subclass for
particular Fc-gRs expressed in the spleen. Consistent
with this, mouse IgG1 (E28 and E34) also did not strongly
promote ADE inC1q/mice. Although further studies are
required, the observation that IgG2a, but not IgG1 or IgG2b,
promotes ADE in C1q/ mice is most consistent with an
interaction with the Fc-gRI (CD64), which primarily binds
monomeric IgG2a with high affinity (Hulett and Hogarth,
1994; Ravetch and Kinet, 1991).
Differences in ADE in vivomay also bemodulated by the
epitope specificity of individual antibodies. In vitro, virtu-
ally all mAbs that neutralize flavivirus infection also en-
hance infection in Fc-gR-expressing cells when used
at subneutralizing concentrations (Morens et al., 1987;
Pierson et al., 2007). Distinct mAbs show unique enhance-
ment profiles in vitro as defined by their peak amplitude
and breadth of enhancement of infection (Morens et al.,
1987; Oliphant et al., 2006). In vivo, mouse IgG2a mAbs
against the DIII-lateral ridge (E24) and DII-fusion loop
(E18) epitopes consistently promoted ADE in C1q/
mice over a relatively broad dose range. Surprisingly, hu-
man or mouse (IgG2b) forms of E16, which also map to the
DIII lateral ridge epitope (Nybakken et al., 2005; Oliphant
et al., 2005), showed little capacity to enhance infection
in wild-type or C1q/mice. At present, it remains unclearlsevier Inc.
Cell Host & Microbe
C1q Inhibits ADE of FlavivirusesFigure 3. C1q Modulates ADE by Polyclonal Mouse and Human Antibody Obtained from WNV- and DENV-Infected Individuals
(A) IgG was purified from naive or WNV immune mouse serum by protein A affinity chromatography. Serial dilutions were mixed with WNV RVP in the
presence or absence of C1q prior to infection of K562 cells. The data are expressed as the fold enhancement of infection compared to no antibody,
and one representative experiment of three is shown.
(B–E) Heat-inactivated serum fromWNV-infected human patients (B and C) or cord blood from DENV-immune mothers (D–F) was serially diluted and
added to WNV or DENV1 RVP in the presence or absence of C1q prior to infection of K562 cells. The data are expressed as the fold enhancement of
infection compared to no antibody. For (B), (D), and (F), one representative experiment of three is shown. Statistical analysis is described in the text.
Error bars indicate standard deviations.why only some mAbs that recognize closely overlapping
epitopes enhance in vivo. Accordingly, we plan to repeat
these studies with mAbs that bind a larger array of epi-
topes on the structural proteins prM and E.
Our in vivo enhancement studies are consistent with
a recent publication that documented ADE of DENV in rhe-
sus macaques after passive transfer of a humanized IgG1
mAb (Goncalvez et al., 2007). As human IgG1 is homolo-
gous to mouse IgG2a, these isotypes interact with similar
classes of Fc-gR (Hulett and Hogarth, 1994; Nimmerjahn
et al., 2005; Ravetch and Kinet, 1991); one apparent differ-
ence, however, is that C1q suppresses ADE of mouse
IgG2a more completely than human IgG1 (compare Fig-
ure 1D and Figure 2A). Although further investigation is
warranted, this could contribute to the distinct ADE phe-
notypes in vivo in C1q-sufficient animals.
The dose of mouse E28 and E34 mAb that promoted
in vivo enhancement in wild-type mice was surprisingly
low (1 ng per mouse) compared to that observed in
K562 cells. Although we cannot explain with certainty
the disparity between in vitro and in vivo findings, the fol-
lowing are three possible explanations. First, the mAbs
appear to neutralize WNV more potently in vivo, inhibiting
infection in the spleen at very low concentrations (10 ng).
As ADE occurs at subneutralizing concentrations of anti-
body, we would expect to see enhancement only at lower
concentrations. Second, the Fc-gR that promotes anti-
body enhancement in the spleen may be different from
our tissue culture model. Virtually nothing is known aboutCell Host &the specific cell or Fc-gR that mediates ADE in vivo. Ex-
periments are planned with specific Fc-gR/ mice to di-
rectly address this question. Third, the tissue’s levels of
antibody are unknown, and specific IgG subclasses could
accumulate differentially in lymphoid tissue because of
antigen trapping by the high density of immune cells that
express particular Fc-gR. Thus, the effective concentra-
tion of antibody in a given tissue compartment could be
distinct.
Few previous studies have examined the interaction of
complement with flaviviruses infection in detail. However,
mice deficient in components of any of the three comple-
ment activation pathways (classical, lectin, or alternative)
showed increased viral burden and lethality after WNV in-
fection (Mehlhop and Diamond, 2006; Mehlhop et al.,
2005). Complement also augmented antibody-mediated
neutralization of WNV infection of BHK cells (Della-Porta
and Westaway, 1977; Mehlhop et al., 2005). In terms of
an association between complement and ADE, one group
observed a serum and, presumably, complement-depen-
dent 10-fold enhancement of WNV infection by a non-
neutralizing IgM antibody (Cardosa et al., 1983, 1986);
although a link between complement, ADE, and IgG sub-
class was suggested, specific complement components
and mAbs of individual IgG subclass were not examined.
ADE has been suggested to contribute to the pathogene-
sis of several other viruses, including HIV and respiratory
syncytial viruses (Fust et al., 1994; Gimenez et al., 1996;
Homsy et al., 1990; Ponnuraj et al., 2001, 2003; TothMicrobe 2, 417–426, December 2007 ª2007 Elsevier Inc. 421
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C1q Inhibits ADE of FlavivirusesFigure 4. Effect of C1q and IgG Subclass on ADE In Vivo
Wild-type (A–C), Fc-gR/ (D and E), or C1q/ (F–H) C57BL/6 mice were pretreated with the indicated doses of anti-WNV mAbs (DII: E18 [mIgG2a]
and E28 [mIgG1]; DIII: E16 [mIgG2b, human IgG subclass variants], E24 [mIgG2a], and E34 [mIgG1]) 1 day prior to infection with 10
2 PFU of WNV. Four
days later, spleens were harvested and homogenized, and virus infection was measured by plaque assay on BHK21 cells. Note at baseline, C1q/
mice lack significant splenic infection because of the absence of an independent entry mechanism that requires C1q (Mehlhop and Diamond, 2006).
The data are expressed as the number of plaque-forming units (PFU) per gram and reflect between four and eight mice per time point. Error bars
indicate standard error of the means. Asterisks indicate differences that were statistically significant ()p < 0.05 and ))p < 0.005). The dotted line
indicates the limit of sensitivity of the assay.et al., 1991). Here, we show that C1q restricts ADE by anti-
flavivirus antibodies in an IgG subclass-specific manner.
Consistent with our data, a recent study with measles
virus showed complement-dependent suppression of ADE
in vitro by a single mAb (Iankov et al., 2006); however,
no analysis of the specific complement components or
IgG subclass was performed.
At present, on a cellular level, we do not know the pre-
cise mechanism by which C1q minimizes ADE. Part of
the difficulty in answering this question is that it remains
unclear exactly how antibody enhances virus infection. Al-
though classical biochemical and microscopic studies
(Gollins and Porterfield, 1984, 1985) suggest that virus
opsonization by subneutralizing concentrations of anti-
bodies enhances cell attachment via a Fc-gR-dependent
mechanism, recent experiments indicate that active
Fc-gR signaling with changes in intracellular innate re-
sponses may contribute to enhanced infection. For exam-
ple, signaling-competent and -incompetent forms of
Fc-gRI and Fc-gRII induced differential enhancement of
DENV immune complex infectivity (Rodrigo et al., 2006).
In addition, ADE reduced antiviral gene transcription
through STAT-1 and NF-kB in macrophages, effectively
increasing the permissiveness of the cell for viral infection
(Mahalingam and Lidbury, 2002). C1q restriction of ADE
could limit virus attachment to cells by directly blocking
Fc-gR binding to the Fc moiety on the antibody heavy
chain. This appears plausible, as C1q is a large multimeric
protein (Kishore and Reid, 2000) and the C1q and Fc-gR422 Cell Host & Microbe 2, 417–426, December 2007 ª2007 Elsbinding sites are proximal (Idusogie et al., 2000, 2001).
Alternatively, C1q could inhibit ADE independently by
attenuating Fc-gR signaling or internalization or directly
restricting structural movements of the envelope protein
that are required for viral fusion (Modis et al., 2004).
Although our experiments demonstrated ADE of WNV
infection in vivo in C1q/mice, we did not observe a sig-
nificant change in disease phenotype or survival. This may
be due to one of several possibilities. First, WNV infection
via a subcutaneous route has a very flat dose-response
curve in C57BL/6 mice such that inoculation of 102 and in-
oculation of 106 plaque-forming units (PFU) have virtually
the same lethality (Diamond et al., 2003a); thus, increased
viral burden in the spleen does not directly lead to en-
hanced dissemination to the brain and spinal cord. Sec-
ond, the linkage between ADE and severe disease as
postulated for DENV infection may not occur for WNV be-
cause one or more additional steps of viral pathogenesis
are absent in the life cycle of WNV. In support of this pos-
sibility, an enhanced risk of severe WNV disease during
secondary infection or vaccine challenge has never been
described. Instead, ADE and severe disease may be
more significant for other flaviviruses, such as DENV. De-
spite much effort, an adequate small animal model of ADE
and DHF/DSS is lacking. As our data establish that C1q
also modulates ADE by DENV infection, we plan to use
C1q/mice and IgG2a mAbs along with specific adapted
DENV strains (Shresta et al., 2006) to evaluate the link be-
tween ADE and pathogenesis.evier Inc.
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explain the increased occurrence of DHF/DSS in infants.
Primary DENV infection of infants from DENV-immune
mothers results in DHF/DSS at a higher frequency than ex-
pected (Halstead et al., 2002; Nguyen et al., 2004). This is
believed to occur as passively transferred anti-DENV anti-
body wanes and binds to virus in a manner that is inade-
quate for neutralization but sufficient for enhancement
(Halstead et al., 2002). Although human IgG1 antibodies
are enriched, anti-DENV antibodies of all IgG subclasses
are present in cord and naive infant blood samples (Wata-
naveeradej et al., 2003), anti-DENV IgG4 antibodies are
higher in patients with DSS (Koraka et al., 2001), and
significant variation in ADE was observed among patient
serum in the presence of C1q (see Figure 3). Infant ADE
may also occur more frequently as serum C1q levels are
33% to 55% lower in the first year of life (Davis et al.,
1979). Thus, the potential for ADE and DHF in infants
with DENV-immune mothers at 6–9 months may be de-
fined bywaning neutralizing titers, IgG subclass specificity
against a particular DENV, and depressed systemic C1q
levels. As DHF is primarily a disease of the developing
world, it is intriguing to consider that IgG subclass skewing
could result from circulating TH2 cytokines that are pres-
ent because of coinfection with parasites (Maizels,
2005). Finally, our experiments may explain why individ-
uals homozygous for the Fc-gRIIa-131H allele are more
susceptible to DHF (Loke et al., 2002): these variant
Fc-gRIIa bind the poorly C1q-fixing hu-IgG2 immune com-
plexes with higher affinity than the Fc-gRIIa-131R allele.
Despite the large number of individuals with circulating
anti-DENV antibodies who become secondarily infected
with a distinct serotype, few (1/200) develop DHF/DSS.
The enhancing activity of maternal or preillness serum
has had conflicting prognostic utility (Kliks et al., 1988,
1989; Laoprasopwattana et al., 2005) for severe DENV
disease. Although more studies are required, addition of
C1q to virus enhancement assays may improve their pre-
dictive value. Finally, our data suggest that development
of adjuvants that favorably skew IgG subclass responses
may be important for vaccines against viruses in which
ADE is a concern.
EXPERIMENTAL PROCEDURES
Cells and Viruses
Vero, K562, and a Raji cell line stably expressing DC-SIGNR were
maintained as described (Pierson et al., 2006, 2007). Mouse bone
marrow-derivedmacrophages were generated andmaintained as pre-
viously described (Samuel et al., 2006). Infections were performed with
WNV RVP that were produced using a previously described com-
plementation strategy (Pierson et al., 2006). The procedures for gener-
ating DENV1 RVPwill be described in greater detail elsewhere (C.A.-S.
and T.C.P., unpublished data). The infectious WNV (3000.0259) strain
was described previously (Ebel et al., 2001).
Mouse Serum and Complement
Blood was collected by axillary venupuncture into serum separator
tubes (Sarsted, Newton, NC) from 8- to 12-week-old male C57BL/6
wild-type, C3/ (Circolo et al., 1999), and C1q/ (Botto et al., 1998)
mice that were obtained commercially (Jackson Laboratories, Bar Har-Cell Host &bor, ME) and from colleagues (C1q/, M. Botto, London, UK; C3/,
H. Molina, St Louis, MO). Blood was clotted on ice and serum was
pooled, aliquoted, and frozen at 80C until use. Heat-inactivated se-
rum was treated at 56C for 30 min. Purified human C1q was obtained
commercially (Advanced Research Technologies, Tyler, TX) and
stored aliquoted at 80C.
In Vitro Enhancement Assays
The enhancing activity of the WNV-reactive mAbs in the presence or
absence of 5% mouse serum or purified C1q (50 mg/ml) was deter-
mined with K562 cells in at least three independent experiments in trip-
licate using a high-throughput flow cytometry-based assay as de-
scribed (Pierson et al., 2006, 2007). Antibody enhancement of WNV
infection was also determined with bone marrow-derived macro-
phages. WNV was preincubated with serial dilutions of antibody in
the presence or absence of mouse serum or purified C1q. Adherent
macrophages were infected with opsonized WNV, washed, and cul-
tured an additional 24 hr. Supernatants were collected and assayed
for production of infectious WNV by viral plaque assay on BHK21 cells
(Diamond et al., 2003a).
E16 Human IgG Subclass Switch Variants
Human IgG subclass switch variants of humanized E16 IgG1 (Oliphant
et al., 2005)were constructedby inserting the humanizedE16VH region
asanNheI-ApaI fragment into respectivepCI-neo-derived vectors con-
taining either the human IgG2, IgG3, or IgG4 constant region cDNA. The
resulting plasmids were cotransfected with humanized E16 light chain
(also in pCI-neo) into HEK293 cells using Lipofectamine 2000 (Invitro-
gen) for production of each IgG subclass switch variant. IgG of different
subclasses were purified from cell supernatants using MabSelect pro-
tein A Sepharose (GE Healthcare) and size exclusion chromatography.
Concentrations were determined by OD280 measurements.
ADE In Vivo
All mice were housed in a pathogen-free mouse facility at Washington
University School of Medicine. Studies were performed in compliance
with the guidelines of the Washington University School of Medicine
Animal Safety Committee. All infections used a low-passage WNV iso-
late 3000.0259 that was propagated once in C6/36 Aedes albopictus
cells. Eight- to twelve-week-old C1q/, Fc-gR I, III, and IV/ (which
lack the common signaling g-chain), and wild-type C57BL/6 mice
were passively transferred mAb by intraperitoneal injection at day 1
and then infected via footpad with 102 PFU of WNV on day 0. Four
days after infection, spleens were removed, weighed, homogenized
using a bead beater apparatus (BioSpec Products, Inc), and titrated
for virus by plaque assay on BHK21 cells as described (Diamond
et al., 2003a).
Statistical Analysis
For in vitro experiments, a pairedStudent’s t testwasused todetermine
statistically significant differences. For viral burden analysis, differ-
ences in titers were analyzed by the Mann-Whitney test. All data were
analyzed using Prism software (GraphPadPrism4, San Diego, CA).
Supplemental Data
The Supplemental Data include two supplemental figures and can be
found with this article online at http://www.cellhostandmicrobe.com/
cgi/content/full/2/6/417/DC1/.
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